SK14572003A3 - Farmaceutická lieková forma amorfného nelfinavir mesylatu - Google Patents

Farmaceutická lieková forma amorfného nelfinavir mesylatu Download PDF

Info

Publication number: SK14572003A3
Authority: SK; Slovakia
Prior art keywords: dosage form; nelfinavir mesylate; copolymer; nelfinavir; mesylate
Prior art date: 2001-05-03

Application number

SK1457-2003A

Other languages

English (en)

Slovak (sk)

Inventor

Martin Howard Infeld

Wantanee Phuapradit

Navnit Hargovindas Shah

Lin Zhang

Original Assignee

F.Hoffmann-La Roche Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-05-03

Filing date

2002-04-29

Publication date

2004-12-01

2002-04-29 Application filed by F.Hoffmann-La Roche Ag filed Critical F.Hoffmann-La Roche Ag

2004-12-01 Publication of SK14572003A3 publication Critical patent/SK14572003A3/sk

Links

NQHXCOAXSHGTIA-SKXNDZRYSA-N nelfinavir mesylate Chemical compound CS(O)(=O)=O.CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 NQHXCOAXSHGTIA-SKXNDZRYSA-N 0.000 title claims abstract description 86
229960005230 nelfinavir mesylate Drugs 0.000 title claims abstract description 82
239000002552 dosage form Substances 0.000 title claims abstract description 26
229920001577 copolymer Polymers 0.000 claims abstract description 27
238000002844 melting Methods 0.000 claims abstract description 17
230000008018 melting Effects 0.000 claims abstract description 17
238000000034 method Methods 0.000 claims abstract description 17
239000007787 solid Substances 0.000 claims abstract description 17
229920001400 block copolymer Polymers 0.000 claims abstract description 14
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims abstract description 12
GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 claims abstract description 10
239000003826 tablet Substances 0.000 claims description 63
239000000203 mixture Substances 0.000 claims description 35
239000008187 granular material Substances 0.000 claims description 25
QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 claims description 24
229960000884 nelfinavir Drugs 0.000 claims description 24
QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 claims description 24
239000000546 pharmaceutical excipient Substances 0.000 claims description 13
238000002156 mixing Methods 0.000 claims description 6
239000003085 diluting agent Substances 0.000 claims description 5
238000010438 heat treatment Methods 0.000 claims description 5
239000007884 disintegrant Substances 0.000 claims description 4
239000000314 lubricant Substances 0.000 claims description 4
239000002904 solvent Substances 0.000 claims description 4
239000000080 wetting agent Substances 0.000 claims description 4
239000011230 binding agent Substances 0.000 claims description 3
239000003381 stabilizer Substances 0.000 claims description 3
239000007894 caplet Substances 0.000 claims description 2
239000002775 capsule Substances 0.000 claims description 2
201000010099 disease Diseases 0.000 claims 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
230000001404 mediated effect Effects 0.000 claims 1
238000002560 therapeutic procedure Methods 0.000 claims 1
239000012943 hotmelt Substances 0.000 abstract description 17
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 17
238000007909 melt granulation Methods 0.000 abstract description 12
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 28
229920001983 poloxamer Polymers 0.000 description 19
239000012458 free base Substances 0.000 description 17
238000004090 dissolution Methods 0.000 description 15
238000009472 formulation Methods 0.000 description 15
235000019359 magnesium stearate Nutrition 0.000 description 14
239000003814 drug Substances 0.000 description 12
229920001993 poloxamer 188 Polymers 0.000 description 11
229920002261 Corn starch Polymers 0.000 description 10
229940079593 drug Drugs 0.000 description 10
URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 10
CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 9
239000011248 coating agent Substances 0.000 description 9
238000000576 coating method Methods 0.000 description 9
229940044519 poloxamer 188 Drugs 0.000 description 9
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 8
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 8
239000003795 chemical substances by application Substances 0.000 description 8
239000000725 suspension Substances 0.000 description 8
239000007916 tablet composition Substances 0.000 description 8
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 7
239000011777 magnesium Substances 0.000 description 7
238000003756 stirring Methods 0.000 description 7
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 6
235000019759 Maize starch Nutrition 0.000 description 6
229920000136 polysorbate Polymers 0.000 description 6
239000008213 purified water Substances 0.000 description 6
ZHXUEUKVDMWSKV-UHFFFAOYSA-N 1-(3,5-ditert-butyl-4-hydroxyphenyl)hex-5-yn-1-one Chemical compound CC(C)(C)C1=CC(C(=O)CCCC#C)=CC(C(C)(C)C)=C1O ZHXUEUKVDMWSKV-UHFFFAOYSA-N 0.000 description 5
229960000913 crospovidone Drugs 0.000 description 5
239000001087 glyceryl triacetate Substances 0.000 description 5
235000013773 glyceryl triacetate Nutrition 0.000 description 5
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 5
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 5
229940124531 pharmaceutical excipient Drugs 0.000 description 5
235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 5
229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 5
239000000843 powder Substances 0.000 description 5
229950003441 tebufelone Drugs 0.000 description 5
229960002622 triacetin Drugs 0.000 description 5
229940023080 viracept Drugs 0.000 description 5
UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 4
229920000168 Microcrystalline cellulose Polymers 0.000 description 4
RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 4
239000000378 calcium silicate Substances 0.000 description 4
229910052918 calcium silicate Inorganic materials 0.000 description 4
OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 4
239000008120 corn starch Substances 0.000 description 4
-1 fatty acid esters Chemical class 0.000 description 4
229940016286 microcrystalline cellulose Drugs 0.000 description 4
235000019813 microcrystalline cellulose Nutrition 0.000 description 4
239000008108 microcrystalline cellulose Substances 0.000 description 4
230000036470 plasma concentration Effects 0.000 description 4
229960000502 poloxamer Drugs 0.000 description 4
239000000454 talc Substances 0.000 description 4
229910052623 talc Inorganic materials 0.000 description 4
239000004408 titanium dioxide Substances 0.000 description 4
238000005550 wet granulation Methods 0.000 description 4
241000725303 Human immunodeficiency virus Species 0.000 description 3
239000008280 blood Substances 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000010408 film Substances 0.000 description 3
239000006186 oral dosage form Substances 0.000 description 3
239000007892 solid unit dosage form Substances 0.000 description 3
229910001220 stainless steel Inorganic materials 0.000 description 3
239000010935 stainless steel Substances 0.000 description 3
229920005682 EO-PO block copolymer Polymers 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
229920001214 Polysorbate 60 Polymers 0.000 description 2
235000012241 calcium silicate Nutrition 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
239000013039 cover film Substances 0.000 description 2
238000000354 decomposition reaction Methods 0.000 description 2
235000014113 dietary fatty acids Nutrition 0.000 description 2
238000001125 extrusion Methods 0.000 description 2
239000000194 fatty acid Substances 0.000 description 2
229930195729 fatty acid Natural products 0.000 description 2
235000013305 food Nutrition 0.000 description 2
238000000227 grinding Methods 0.000 description 2
239000011874 heated mixture Substances 0.000 description 2
JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 2
238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
125000006353 oxyethylene group Chemical group 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
229940069328 povidone Drugs 0.000 description 2
238000005070 sampling Methods 0.000 description 2
239000007962 solid dispersion Substances 0.000 description 2
239000007921 spray Substances 0.000 description 2
AWGBKZRMLNVLAF-UHFFFAOYSA-N 3,5-dibromo-n,2-dihydroxybenzamide Chemical compound ONC(=O)C1=CC(Br)=CC(Br)=C1O AWGBKZRMLNVLAF-UHFFFAOYSA-N 0.000 description 1
108010016183 Human immunodeficiency virus 1 p16 protease Proteins 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000000654 additive Substances 0.000 description 1
238000013019 agitation Methods 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000001760 anti-analgesic effect Effects 0.000 description 1
230000000843 anti-fungal effect Effects 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
239000002221 antipyretic Substances 0.000 description 1
229940125716 antipyretic agent Drugs 0.000 description 1
FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000003181 co-melting Methods 0.000 description 1
239000007891 compressed tablet Substances 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
238000001816 cooling Methods 0.000 description 1
229940099112 cornstarch Drugs 0.000 description 1
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
238000007922 dissolution test Methods 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
238000009506 drug dissolution testing Methods 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000000694 effects Effects 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
239000007888 film coating Substances 0.000 description 1
238000009501 film coating Methods 0.000 description 1
239000012530 fluid Substances 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
230000036737 immune function Effects 0.000 description 1
KHLVKKOJDHCJMG-QDBORUFSSA-L indigo carmine Chemical compound [Na+].[Na+].N/1C2=CC=C(S([O-])(=O)=O)C=C2C(=O)C\1=C1/NC2=CC=C(S(=O)(=O)[O-])C=C2C1=O KHLVKKOJDHCJMG-QDBORUFSSA-L 0.000 description 1
239000004179 indigotine Substances 0.000 description 1
235000012738 indigotine Nutrition 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000001050 lubricating effect Effects 0.000 description 1
238000005461 lubrication Methods 0.000 description 1
229940057948 magnesium stearate Drugs 0.000 description 1
239000002736 nonionic surfactant Substances 0.000 description 1
239000008203 oral pharmaceutical composition Substances 0.000 description 1
239000012663 orally bioavailable inhibitor Substances 0.000 description 1
229940044205 orally bioavailable inhibitor Drugs 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
238000005063 solubilization Methods 0.000 description 1
230000007928 solubilization Effects 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000008399 tap water Substances 0.000 description 1
235000020679 tap water Nutrition 0.000 description 1
238000012360 testing method Methods 0.000 description 1
238000000870 ultraviolet spectroscopy Methods 0.000 description 1
230000029812 viral genome replication Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Virology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Molecular Biology (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

SK1457-2003A 2001-05-03 2002-04-29 Farmaceutická lieková forma amorfného nelfinavir mesylatu SK14572003A3 (sk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US28841001P	2001-05-03	2001-05-03
PCT/EP2002/004711 WO2002089835A2 (en)	2001-05-03	2002-04-29	Pharmaceutical dosage form of amorphous nelfinavir mesylate

Publications (1)

Publication Number	Publication Date
SK14572003A3 true SK14572003A3 (sk)	2004-12-01

Family

ID=23106974

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1457-2003A SK14572003A3 (sk)	2001-05-03	2002-04-29	Farmaceutická lieková forma amorfného nelfinavir mesylatu

Country Status (36)

Country	Link
US (1)	US7014866B2 (pl)
EP (1)	EP1390063B1 (pl)
JP (1)	JP4101661B2 (pl)
KR (1)	KR100554816B1 (pl)
CN (1)	CN1255185C (pl)
AR (1)	AR034320A1 (pl)
AT (1)	ATE282428T1 (pl)
BG (1)	BG108311A (pl)
BR (1)	BR0209325A (pl)
CA (1)	CA2444116C (pl)
CZ (1)	CZ20033211A3 (pl)
DE (1)	DE60201988T2 (pl)
EA (1)	EA006627B1 (pl)
EC (1)	ECSP034827A (pl)
ES (1)	ES2231717T3 (pl)
GE (1)	GEP20053466B (pl)
GT (1)	GT200200079A (pl)
HR (1)	HRP20030873B1 (pl)
HU (1)	HU229938B1 (pl)
IL (2)	IL158306A0 (pl)
IS (1)	IS7010A (pl)
JO (1)	JO2401B1 (pl)
MA (1)	MA27018A1 (pl)
MX (1)	MXPA03009971A (pl)
MY (1)	MY128509A (pl)
NO (1)	NO20034689L (pl)
NZ (1)	NZ528689A (pl)
PA (1)	PA8544501A1 (pl)
PE (1)	PE20021159A1 (pl)
PL (1)	PL366998A1 (pl)
PT (1)	PT1390063E (pl)
RS (1)	RS83503A (pl)
SK (1)	SK14572003A3 (pl)
TW (1)	TWI234461B (pl)
UA (1)	UA76463C2 (pl)
WO (1)	WO2002089835A2 (pl)

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2001034119A2 (en)	1999-11-12	2001-05-17	Abbott Laboratories	Inhibitors of crystallization in a solid dispersion
DE10026698A1 (de)	2000-05-30	2001-12-06	Basf Ag	Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
CA2398226A1 (en) *	2002-01-28	2003-07-28	Pfizer Inc.	Increased-dosage nelfinavir tablet and method of making same
WO2005004868A1 (ja) *	2003-07-15	2005-01-20	Arigen, Inc.	抗コロナウイルス剤
US8025899B2 (en)	2003-08-28	2011-09-27	Abbott Laboratories	Solid pharmaceutical dosage form
US8377952B2 (en) *	2003-08-28	2013-02-19	Abbott Laboratories	Solid pharmaceutical dosage formulation
US8974823B2 (en) *	2003-12-31	2015-03-10	Bend Research, Inc.	Solid compositions of low-solubility drugs and poloxamers
JP5228488B2 (ja) *	2004-12-03	2013-07-03	メルク・シャープ・アンド・ドーム・コーポレーション	放出速度調節組成物を含有しているカルボキサミドｈｉｖインテグラーゼ阻害薬の医薬配合物
SI1928427T1 (sl) *	2005-09-23	2010-03-31	Hoffmann La Roche	Nove formulacije za doziranje
ES2350497T3 (es) *	2005-12-14	2011-01-24	F. Hoffmann-La Roche Ag	Formulación de profármacos para el vhc.
ATE482690T1 (de) *	2005-12-14	2010-10-15	Hoffmann La Roche	Hcv-prodrug-formulierung
WO2008017867A2 (en) *	2006-08-10	2008-02-14	Cipla Limited	Antiretroviral solid oral composition with at least one water insoluble polymer
KR101462693B1 (ko)	2006-08-16	2014-11-17	노파르티스 아게	고도 결정질 치료용 화합물의 고체 분산체 제조 방법
CA2669938C (en) *	2006-11-15	2016-01-05	Abbott Laboratories	Solid pharmaceutical dosage formulations
CA2681628C (en)	2007-03-16	2016-10-18	Concert Pharmaceuticals, Inc.	Inhibitors of cholesterol ester transfer protein
KR20100105802A (ko) *	2007-04-19	2010-09-29	콘서트 파마슈티컬즈, 인크.	중수소화된 모르폴리닐 화합물
ES2401914T3 (es)	2007-04-25	2013-04-25	Concert Pharmaceuticals Inc.	Análogos de Cilostazol
CA2630084A1 (en) *	2007-04-30	2008-10-30	Mark Andreychuk	Coiled tubing with retainer for conduit
US9194512B2 (en)	2007-04-30	2015-11-24	Mark Andreychuk	Coiled tubing with heat resistant conduit
MX385316B (es)	2007-05-01	2025-03-18	Concert Pharmaceuticals Inc	Compuestos de morfinano.
AU2008247818B2 (en)	2007-05-01	2011-10-20	Sun Pharmaceutical Industries, Inc.	Morphinan compounds
WO2008137461A1 (en) *	2007-05-01	2008-11-13	Concert Pharmaceuticals Inc.	Naphthyl(ethyl) acetamides
EP4183787A1 (en)	2007-05-01	2023-05-24	Concert Pharmaceuticals Inc.	Morphinan compounds
KR20120029480A (ko)	2007-06-12	2012-03-26	콘서트 파마슈티컬즈, 인크.	아자펩티드 유도체
EP2212298B1 (en) *	2007-10-18	2013-03-27	Concert Pharmaceuticals Inc.	Deuterated etravirine
WO2009052391A1 (en) *	2007-10-19	2009-04-23	Purdue Research Foundation	Solid formulations of crystalline compounds
ITMI20080227A1 (it) *	2008-02-13	2009-08-14	Felice Vinati	'' dispositivo di sicurezza per apparati di sollevamento a fune ''
KR20100121527A (ko)	2008-02-29	2010-11-17	콘서트 파마슈티컬즈, 인크.	치환된 잔틴 유도체
US20110160253A1 (en) *	2008-05-28	2011-06-30	Harbeson Scott L	Deuterated tizanidine
US20100221221A1 (en) *	2008-08-12	2010-09-02	Concert Pharmaceuticals Inc.	N-phenyl-2-pyrimidineamine derivatives
MX361542B (es)	2008-09-19	2018-12-10	Concert Pharmaceuticals Inc	Compuestos de morfinan.
US20120083487A1 (en)	2008-10-30	2012-04-05	Amanda Thomas	Combination of morphinan compounds and antidepressant for the treatment of pseudobulbar affect, neurolgical diseases, intractable and chronic pain and brain injury
US20120053169A1 (en)	2008-10-30	2012-03-01	Amanda Thomas	Combination of morphinan compounds and antidepressant for the treatment of pseudobulbar affect, neurological diseases, intractable and chronic pain and brain injury
US9096646B2 (en)	2008-11-04	2015-08-04	Anchor Therapeutics, Inc.	CXCR4 receptor compounds
WO2010065755A1 (en)	2008-12-04	2010-06-10	Concert Pharmaceuticals, Inc.	Deuterated pyridinones
US20110053961A1 (en)	2009-02-27	2011-03-03	Concert Pharmaceuticals, Inc.	Substituted xanthine derivatives
BRPI1009199A2 (pt)	2009-03-17	2016-03-08	Concert Pharmaceuticals Inc	compostos de pirazinoisoquinolina
US20120244122A1 (en)	2009-05-28	2012-09-27	Masse Craig E	Peptides for the Treatment of HCV Infections
US8501738B2 (en)	2009-06-23	2013-08-06	Concert Pharmaceuticals, Inc.	Substituted triazolo-pyridazine derivatives
US20110015154A1 (en) *	2009-07-20	2011-01-20	Kellermann Gottfried H	Supporting acetylcholine function
WO2011047315A1 (en)	2009-10-15	2011-04-21	Concert Pharmaceuticals, Inc.	Subsitituted benzimidazoles
US20110098265A1 (en) *	2009-10-28	2011-04-28	Neuroscience, Inc.	Methods for reducing cravings and impulses associated with addictive and compulsive behaviors
WO2011060216A1 (en)	2009-11-12	2011-05-19	Concert Pharmaceuticals Inc.	Substituted azaindoles
US20140018379A1 (en)	2010-02-18	2014-01-16	Concert Pharmaceuticals Inc.	Pyrimidine derivatives
WO2011106703A2 (en)	2010-02-26	2011-09-01	Anchor Therapeutics, Inc.	Cxcr4 receptor compounds
US8575361B2 (en)	2010-03-02	2013-11-05	Concert Pharmaceuticals Inc.	Tetrahydronaphthalene derivatives
US8513434B2 (en)	2010-03-02	2013-08-20	Concert Pharmaceuticals Inc.	Tetrahydronaphthalene derivatives
WO2011157721A2 (en)	2010-06-14	2011-12-22	Ratiopharm Gmbh	Ivabradine-containing pharmaceutical composition
EP2616467A1 (en)	2010-09-13	2013-07-24	Concert Pharmaceuticals Inc.	Substituted azaindoles
EP2455068A1 (en) *	2010-11-09	2012-05-23	F. Hoffmann-La Roche AG	Pharmaceutical composition for treating HCV infections
WO2012065028A2 (en)	2010-11-11	2012-05-18	Concert Pharmaceuticals Inc.	Substituted tetracyclines
WO2012079075A1 (en)	2010-12-10	2012-06-14	Concert Pharmaceuticals, Inc.	Deuterated phthalimide derivatives
US8447329B2 (en)	2011-02-08	2013-05-21	Longsand Limited	Method for spatially-accurate location of a device using audio-visual information
EP2678337A1 (en)	2011-02-25	2014-01-01	Concert Pharmaceuticals Inc.	2-amino-naphthyridine derivatives
WO2012129381A1 (en)	2011-03-22	2012-09-27	Concert Pharmaceuticals Inc.	Deuterated preladenant
WO2012151361A1 (en)	2011-05-03	2012-11-08	Concert Pharmaceuticals Inc.	Carbamoylpyridone derivatives
WO2012154728A1 (en)	2011-05-10	2012-11-15	Concert Pharmaceuticals Inc.	Deuterated n-butyl bumetanide
DK3235812T3 (da)	2011-05-18	2019-11-25	Vertex Pharmaceuticals Europe Ltd	Deutererede derivater af ivacaftor
WO2013013052A1 (en)	2011-07-19	2013-01-24	Concert Pharmaceuticals, Inc.	Substituted xanthine derivatives
FR2985177B1 (fr) *	2012-01-02	2016-04-01	Oreal	Composition cosmetique solide aqueuse comprenant de l'alkylcellulose, au moins deux huiles non volatiles et au moins deux agents tensioactifs
EP2802596A1 (en)	2012-01-09	2014-11-19	Anchor Therapeutics, Inc.	Apj receptor compounds
WO2013130849A1 (en)	2012-02-29	2013-09-06	Concert Pharmaceuticals, Inc.	Substituted dioxopiperidinyl phthalimide derivatives
KR20150002779A (ko)	2012-04-13	2015-01-07	콘서트 파마슈티컬즈, 인크.	치환된 크산틴 유도체
US9249093B2 (en)	2012-04-20	2016-02-02	Concert Pharmaceuticals, Inc.	Deuterated rigosertib
DK3882249T3 (da)	2012-06-15	2025-08-25	Sun Pharmaceutical Ind Inc	Deutererede derivater af ruxolitinib
EP2885267B1 (en)	2012-07-12	2018-09-05	Concert Pharmaceuticals, Inc.	Deuterated idebenone
EP3492472A1 (en)	2012-08-17	2019-06-05	Concert Pharmaceuticals Inc.	Deuterated baricitinib with improved metabolic stability as jak1 and jak2 kinase inhibitor for treating e.g. rheumatoid arthritis
WO2014078842A1 (en)	2012-11-19	2014-05-22	Concert Pharmaceuticals, Inc.	Deuterated cftr potentiators
US20150299166A1 (en)	2012-12-20	2015-10-22	Concert Pharmaceuticals, Inc.	Deuterated alk inhibitors
ES2882258T3 (es)	2012-12-21	2021-12-01	Mayo Found Medical Education & Res	Métodos y materiales para tratar estenosis de la válvula aórtica calcificada
WO2014110322A2 (en)	2013-01-11	2014-07-17	Concert Pharmaceuticals, Inc.	Substituted dioxopiperidinyl phthalimide derivatives
CA2904054A1 (en)	2013-03-15	2014-09-25	Concert Pharmaceuticals, Inc.	Deuterated palbociclib
CA2906396A1 (en)	2013-03-15	2014-09-25	Concert Pharmaceuticals Inc.	Inhibitors of the enzyme udp-glucose: n-acyl-sphingosine glucosyltransferase
HU231191B1 (hu)	2013-04-15	2021-08-30	Szegedi Tudományegyetem	Izotóp tartalmú morfin molekulák
WO2015010045A1 (en)	2013-07-18	2015-01-22	Anchor Therapeutics, Inc.	Apj receptor compounds
WO2015009889A1 (en)	2013-07-18	2015-01-22	Concert Pharmaceuticals, Inc.	Deuterated intedanib derivatives and their use for the treatment of proliferative disorders
US9676790B2 (en)	2013-08-30	2017-06-13	Concert Pharmaceuticals, Inc.	Substituted thienotriazolodiazapines
EP3105232B1 (en)	2014-02-10	2019-08-28	Concert Pharmaceuticals Inc.	Substituted triazolobenzodiazepines
US20170216296A1 (en)	2014-04-18	2017-08-03	Concert Pharmaceuticals, Inc.	Methods of treating hyperglycemia
WO2015179772A1 (en)	2014-05-23	2015-11-26	Concert Pharmaceuticals, Inc.	Deuterated phenylquinazolinone and phenylisoquinolinone compounds
PE20170664A1 (es)	2014-06-06	2017-06-10	Res Triangle Inst	Agonistas del receptor de apelina(apj) y usos de los mismos
EP4180041A1 (en)	2014-08-07	2023-05-17	Mayo Foundation for Medical Education and Research	Compounds and methods for treating cancer
WO2016061488A1 (en)	2014-10-17	2016-04-21	Concert Pharmaceuticals, Inc.	Amine reuptake inhibitors
WO2016073545A1 (en)	2014-11-06	2016-05-12	Concert Pharmaceuticals, Inc.	Phenyloxadiazole benzoic acids
WO2016089814A1 (en)	2014-12-02	2016-06-09	Concert Pharmaceuticals, Inc.	Deuterated analogues of daclatasvir
WO2016094011A1 (en) *	2014-12-11	2016-06-16	Merck Sharp & Dohme Corp.	Crystal forms of a ccr5 antagonist
CN105769809A (zh) *	2014-12-23	2016-07-20	上海星泰医药科技有限公司	提高生物利用度的雷尼司他及其制备方法
WO2016105547A1 (en)	2014-12-24	2016-06-30	Concert Pharmaceuticals, Inc.	Deuterated dasabuvir
WO2016109795A1 (en)	2014-12-31	2016-07-07	Concert Pharmaceuticals, Inc.	Deuterated funapide and difluorofunapide
EP3265440A1 (en)	2015-03-06	2018-01-10	Concert Pharmaceuticals Inc.	Deuterated emricasan
HK1249893A1 (zh)	2015-03-31	2018-11-16	Vertex Pharmaceuticals (Europe) Limited	氘代vx-661
US10683305B2 (en)	2015-04-27	2020-06-16	Concert Pharmaceuticals, Inc.	Deuterated OTX-015
WO2017020002A1 (en)	2015-07-30	2017-02-02	Concert Pharmaceuticals, Inc.	Deuterated morphinan compounds for use in treating agitation
WO2017020005A1 (en)	2015-07-30	2017-02-02	Concert Pharmaceuticals, Inc.	Morphinan compounds for use in treating agitation
US20180353500A1 (en)	2015-09-21	2018-12-13	Vertex Pharmaceuticals (Europe) Limited	Administration of deuterated cftr potentiators
US11267777B2 (en)	2015-11-19	2022-03-08	Concert Pharmaceuticals, Inc.	Deuterated EPI-743
PE20190258A1 (es)	2015-12-09	2019-02-25	Res Triangle Inst	Antagonistas del receptor de la apelina (apj) mejorados y usos de los mismos
WO2017147003A1 (en)	2016-02-26	2017-08-31	Novobiotic Pharmaceuticals, Llc	Novel macrocyclic antibiotics and uses thereof
LT3452039T (lt)	2016-05-04	2024-10-25	Sun Pharmaceutical Industries, Inc.	Plaukų slinkimo sutrikimo gydymas deuterintais jak inhibitoriais
CN115215801A (zh)	2016-07-04	2022-10-21	雅芳制药公司	氘代右美沙芬的合成方法
CN109789103A (zh)	2016-08-01	2019-05-21	布里格姆妇女医院	用于递送蛋白质和肽的颗粒
US10696677B2 (en)	2016-12-21	2020-06-30	Research Triangle Institute	Diaryl purine derivatives with improved bioavailability
EP3589659B1 (en)	2017-02-28	2025-04-09	Mayo Foundation for Medical Education and Research	Combinations for use in the treatment of cancer
US11278025B2 (en)	2017-05-17	2022-03-22	The General Hospital Corporation	Antibiotic compounds
CA3063953A1 (en)	2017-05-19	2018-11-22	Superb Wisdom Limited	Derivatives of resiquimod
AU2018371784B2 (en)	2017-11-22	2024-10-17	Sun Pharmaceutical Industries, Inc.	Deuterated analogs of D-serine and uses thereof
US11243207B2 (en)	2018-03-29	2022-02-08	Mayo Foundation For Medical Education And Research	Assessing and treating cancer
MX2021012409A (es)	2019-04-10	2021-11-12	Mayo Found Medical Education & Res	Metodos y materiales para el tratamiento dependiente del genero de la disfuncion cardiovascular.
WO2021236139A1 (en)	2020-05-21	2021-11-25	Concert Pharmaceuticals, Inc.	Novel deuterated jak inhibitor and uses thereof
CA3184471A1 (en)	2020-05-27	2021-12-02	The Penn State Research Foundation	Antibacterial compounds
IL302401A (en)	2020-10-28	2023-06-01	Sun Pharmaceutical Ind Inc	Regimens for the treatment of hair loss disorders with faded JAC inhibitors
JP2024507574A (ja)	2021-02-25	2024-02-20	リサーチトライアングルインスティテュート	アペリン受容体アゴニストとしてのヘテロアリール誘導体
CN118159272A (zh)	2021-08-11	2024-06-07	太阳医药工业公司	用氘化的jak抑制剂来治疗脱发病症
EP4384173A1 (en)	2021-08-12	2024-06-19	Sun Pharmaceutical Industries, Inc.	Treatment of jak-inhibition-responsive disorders with prodrugs of jak inhibitors
EP4518863A1 (en)	2022-05-04	2025-03-12	Sun Pharmaceutical Industries, Inc.	Dosage regimens for treatment with deuterated jak inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5281420A (en)	1992-05-19	1994-01-25	The Procter & Gamble Company	Solid dispersion compositions of tebufelone
IE80467B1 (en) *	1995-07-03	1998-07-29	Elan Corp Plc	Controlled release formulations for poorly soluble drugs
US5834472A (en)	1996-05-24	1998-11-10	Schering Corporation	Antifungal composition with enhanced bioavailability
US6232333B1 (en) *	1996-11-21	2001-05-15	Abbott Laboratories	Pharmaceutical composition
US6045829A (en) *	1997-02-13	2000-04-04	Elan Pharma International Limited	Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
US6001851A (en)	1997-03-13	1999-12-14	Agouron Pharmaceuticals, Inc.	HIV protease inhibitors
ES2248908T7 (es) *	1997-06-06	2014-11-24	Depomed, Inc.	Formas de dosificación de fármacos por vía oral y retención gástrica para liberación continuada de fármacos altamente solubles
AU8145198A (en) *	1997-06-16	1999-01-04	Vertex Pharmaceuticals Incorporated	Methods of increasing the bioavailability of stable crystal polymorphs of a compound
ES2236943T3 (es) *	1997-09-19	2005-07-16	Shire Laboratories Inc.	Perlas de disolucion solida.
DE60017444T2 (de) *	1999-11-12	2006-02-09	Abbott Laboratories, Abbott Park	Pharmazeutische formulierungen auf basis fester dispersionen
US6499984B1 (en) *	2000-05-22	2002-12-31	Warner-Lambert Company	Continuous production of pharmaceutical granulation

2002
- 2002-04-29 PT PT02748680T patent/PT1390063E/pt unknown
- 2002-04-29 KR KR1020037014234A patent/KR100554816B1/ko not_active Expired - Fee Related
- 2002-04-29 JP JP2002586967A patent/JP4101661B2/ja not_active Expired - Fee Related
- 2002-04-29 CA CA002444116A patent/CA2444116C/en not_active Expired - Fee Related
- 2002-04-29 EP EP02748680A patent/EP1390063B1/en not_active Expired - Lifetime
- 2002-04-29 SK SK1457-2003A patent/SK14572003A3/sk unknown
- 2002-04-29 DE DE60201988T patent/DE60201988T2/de not_active Expired - Lifetime
- 2002-04-29 EA EA200301166A patent/EA006627B1/ru not_active IP Right Cessation
- 2002-04-29 RS YU83503A patent/RS83503A/sr unknown
- 2002-04-29 IL IL15830602A patent/IL158306A0/xx unknown
- 2002-04-29 PL PL02366998A patent/PL366998A1/pl unknown
- 2002-04-29 GE GE5295A patent/GEP20053466B/en unknown
- 2002-04-29 HU HU0401238A patent/HU229938B1/hu not_active IP Right Cessation
- 2002-04-29 NZ NZ528689A patent/NZ528689A/en unknown
- 2002-04-29 CN CNB028092953A patent/CN1255185C/zh not_active Expired - Fee Related
- 2002-04-29 BR BR0209325-1A patent/BR0209325A/pt not_active Application Discontinuation
- 2002-04-29 CZ CZ20033211A patent/CZ20033211A3/cs unknown
- 2002-04-29 HR HR20030873A patent/HRP20030873B1/xx not_active IP Right Cessation
- 2002-04-29 MX MXPA03009971A patent/MXPA03009971A/es active IP Right Grant
- 2002-04-29 AT AT02748680T patent/ATE282428T1/de active
- 2002-04-29 ES ES02748680T patent/ES2231717T3/es not_active Expired - Lifetime
- 2002-04-29 UA UA20031210981A patent/UA76463C2/uk unknown
- 2002-04-29 WO PCT/EP2002/004711 patent/WO2002089835A2/en not_active Ceased
- 2002-04-30 MY MYPI20021591A patent/MY128509A/en unknown
- 2002-04-30 AR ARP020101580A patent/AR034320A1/es not_active Application Discontinuation
- 2002-04-30 PA PA20028544501A patent/PA8544501A1/es unknown
- 2002-04-30 PE PE2002000369A patent/PE20021159A1/es not_active Application Discontinuation
- 2002-04-30 TW TW091108967A patent/TWI234461B/zh not_active IP Right Cessation
- 2002-05-01 JO JO200237A patent/JO2401B1/en active
- 2002-05-02 GT GT200200079A patent/GT200200079A/es unknown
- 2002-05-02 US US10/138,071 patent/US7014866B2/en not_active Expired - Fee Related
2003
- 2003-10-08 IL IL158306A patent/IL158306A/en not_active IP Right Cessation
- 2003-10-20 NO NO20034689A patent/NO20034689L/no not_active Application Discontinuation
- 2003-10-30 IS IS7010A patent/IS7010A/is unknown
- 2003-10-31 EC EC2003004827A patent/ECSP034827A/es unknown
- 2003-11-03 BG BG108311A patent/BG108311A/bg unknown
- 2003-11-03 MA MA27379A patent/MA27018A1/fr unknown

Also Published As

Publication number	Publication date
TWI234461B (en)	2005-06-21
PT1390063E (pt)	2005-03-31
CA2444116A1 (en)	2002-11-14
MXPA03009971A (es)	2004-02-12
HRP20030873A2 (en)	2005-08-31
PL366998A1 (pl)	2005-02-07
CA2444116C (en)	2009-01-20
PA8544501A1 (es)	2002-11-18
PE20021159A1 (es)	2002-12-20
NO20034689D0 (no)	2003-10-20
EA200301166A1 (ru)	2004-04-29
AR034320A1 (es)	2004-02-18
DE60201988D1 (de)	2004-12-23
US7014866B2 (en)	2006-03-21
HUP0401238A2 (hu)	2004-12-28
MY128509A (en)	2007-02-28
GEP20053466B (en)	2005-02-25
KR20040007523A (ko)	2004-01-24
ES2231717T3 (es)	2005-05-16
NZ528689A (en)	2005-03-24
EP1390063A2 (en)	2004-02-25
EA006627B1 (ru)	2006-02-24
HU229938B1 (en)	2015-01-28
ECSP034827A (es)	2003-12-24
EP1390063B1 (en)	2004-11-17
MA27018A1 (fr)	2004-12-20
BR0209325A (pt)	2004-07-20
DE60201988T2 (de)	2005-12-15
RS83503A (sr)	2006-10-27
CN1255185C (zh)	2006-05-10
UA76463C2 (en)	2006-08-15
CN1547484A (zh)	2004-11-17
US20030021840A1 (en)	2003-01-30
KR100554816B1 (ko)	2006-02-22
ATE282428T1 (de)	2004-12-15
HK1070285A1 (en)	2005-06-17
JP2004527569A (ja)	2004-09-09
HUP0401238A3 (en)	2012-09-28
IL158306A (en)	2008-11-03
HRP20030873B1 (en)	2006-04-30
JO2401B1 (en)	2007-06-17
IS7010A (is)	2003-10-30
GT200200079A (es)	2002-12-05
BG108311A (bg)	2004-12-30
IL158306A0 (en)	2004-05-12
NO20034689L (no)	2003-10-20
CZ20033211A3 (cs)	2004-09-15
JP4101661B2 (ja)	2008-06-18
WO2002089835A2 (en)	2002-11-14
WO2002089835A3 (en)	2003-05-01

Legal Events

Date	Code	Title	Description
2011-11-04	FB9A	Suspension of patent application procedure

Publication	Publication Date	Title
KR100554816B1 (ko)	2006-02-22	비결정질 넬피나비르 메실레이트의 약학 제형
JP3162626B2 (ja)	2001-05-08	イルベサルタン含有医薬組成物
US7976869B2 (en)	2011-07-12	Fenofibrate tablets
JP2010280707A (ja)	2010-12-16	メシル酸サキナビル経口投与剤型
JP5318400B2 (ja)	2013-10-16	レボフロキサシン含有錠剤
WO2024095296A1 (en)	2024-05-10	Solvent free solid oral composition of bcs class iv drugs
AU2002319154B2 (en)	2007-03-08	Pharmaceutical dosage form of amorphous nelfinavir mesylate
WO2008091957A2 (en)	2008-07-31	Pharmaceutical compositions containing famotidine and ibuprofen and having improved content uniformity
AU2002319154A1 (en)	2003-05-01	Pharmaceutical dosage form of amorphous nelfinavir mesylate
HK1070285B (en)	2006-08-18	Pharmaceutical dosage form of amorphous nelfinavir mesylate
WO2016042566A1 (en)	2016-03-24	Extended release formulation of trimetazidine
HK1184690A (en)	2014-01-30	Bioavailable solid dosage forms of metaxalone
HK1002384B (en)	2004-03-05	Pharmaceutical compositions containing irbesartan